Muhammad Ilham Dhiya Rakasiwi

Muhammad Ilham Dhiya Rakasiwi


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2024 in Narra J
Verified
Journal Article
Open access
PDF file
MRMuhammad Ilham Dhiya Rakasiwi
Muhammad Ilham Dhiya Rakasiwi
SASalsabila R. Andini
Salsabila R. Andini
HAHanna L. Afladhia
Hanna L. Afladhia
MRMuhammad Ilham Dhiya Rakasiwi
Muhammad Ilham Dhiya Rakasiwi
EBErlina Burhan
Erlina Burhan
Liver injury in tuberculosis patients, associated with noncompliance with treatment, is further exacerbated by viral hepatitis, which not only directly harms the liver but also increases susceptibility to drug-induced liver injury. The aim of this study was to analyze the associated risk factors for viral hepatitis in tuberculosis patients. This systematic review and meta-analysis adhere to the PRISMA 2020 statement, and the protocol has been registered with PROSPERO (CRD42023477241). Screening and selection of articles were carried out according to predetermined inclusion and exclusion criteria, utilizing four databases: Embase, Medline, Scopus, and ProQuest. Baseline characteristics and patient-related risk factors from each included study were extracted, followed by a meta-analysis of factors that potentially had significance, with the heterogeneities also being analyzed. Of the 21 included studies out of 6,415 identified records, 12 potential risk factors for hepatitis B and 15 for hepatitis C were subjected to meta-analysis. Some key risk factors included for hepatitis B and C were HIV infection (OR: 3.42; 95%CI: 2.19–5.34 and OR: 6.99; 95%CI: 5.09–9.61, respectively), smoking (OR: 1.55; 95%CI: 1.19–2.02 and OR: 3.06; 95%CI: 1.63–5.75, respectively) and alcohol consumption (OR: 2.38; 95%CI: 1.06–5.37 and OR: 4.32; 95%CI: 2.76–6.78, respectively). Furthermore, meta-analysis indicated that other significant risk factors for hepatitis B and/or C include injecting and non-injecting drug use, multiple sexual partners, tattooing, ear-nose piercing, blood transfusion, dental interventions, homelessness, incarceration, living with prisoners, sexually transmitted diseases, and diabetes mellitus. In conclusion, patients with tuberculosis who have risk factors such as smoking, HIV, or alcohol consumption should be screened for hepatitis B and C to prevent liver injury.

9 June 2025 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EBErlina Burhan
Erlina Burhan
FAFarchan Azzumar
Farchan Azzumar
FSFira Alyssa Gabriella Sinuraya
Fira Alyssa Gabriella Sinuraya
SPSabarinah Prasetyo
Sabarinah Prasetyo
DGDwi Gayatri
Dwi Gayatri
EWElvan Wiyarta
Elvan Wiyarta
Background: Vaccination was included in the Indonesian government policy to address Delta and Omicron waves of SAR-CoV-2 infections. This study assesses the effectiveness of inactivated (CoronaVac, BBIBP-Cor) and mRNA vaccines (mRNA-1273, BNT162b2) against COVID-19 regardless of symptoms and fatal COVID-19 (mortality within 30 days after confirmed RT-PCR) during Delta and Omicron period in Jakarta, Indonesia. Methods: This study case-control, test-negative study included all individuals aged over 18 years in Jakarta with complete and consistent SARS-CoV-2 RT-PCR results from 1 June to 31 August 2021 (Delta period) and 1 January to 2 April 2022 (Omicron period), as well as complete vaccination status. This study integrates several public health data from the Jakarta provincial government. From the odds ratio, vaccine effectiveness (VE) was analyzed as the primary outcome using unmatched analysis, matched analysis, and adjustments for other factors. Results: This study includes 982,885 eligible subjects recorded from March 2021 to April 2022. All subjects generally underwent testing 4–9 weeks after their last vaccine dose. The VE of 2-dose inactivated vaccine against SARS-CoV-2 infection during Delta wave was 22.06% (95% CI 20.63–24.54) and the VE against fatal COVID-19 was 78.55% (95% CI 72.91–83.00). A complete primary dose of mRNA vaccine showed VE of 24.81% (95% CI 16.81–32.09) against infection during Omicron wave. Furthermore an additional mRNA booster dose showed VE of 68.82% (95% CI 54.11–78.82) based on unmatched analysis. Conclusion: A complete primary dose of inactivated vaccine provided mild protection against COVID-19 and essential protection against fatal cases during the Delta wave, but offered little to no protection during the Omicron wave. In contrast, the mRNA vaccine, either as primary vaccination, homologous, or heterologous booster regimen, conferred acceptable protection against Omicron. This study recommends real-world vaccination strategies for LMICs with typical vaccine supply constraints.

31 July 2025 in Majalah Biomorfologi
Verified
Journal Article
Open access
PDF file
RFRayhan Farandy
Rayhan Farandy
MRMuhammad Ilham Dhiya Rakasiwi
Muhammad Ilham Dhiya Rakasiwi
MRMuhammad Ilham Dhiya Rakasiwi
Muhammad Ilham Dhiya Rakasiwi
NKNurul Gusti Khatimah
Nurul Gusti Khatimah
Highlights ABSTRACT Background: Every year, over 13.7 million individuals experience strokes, resulting in approximately 5.8 million deaths. C-type lectin-like receptor 2 (CLEC-2) plays a significant role in platelet activation, which is elevated in ischemic stroke and is associated with disease progression and prognosis. Objective: To review the literature on the potential of CLEC-2 as a biomarker for assessing the prognosis and progression of ischemic stroke. Material and Method: This rapid review followed the Cochrane interim guidelines and adhered to PRISMA standards. A comprehensive search was conducted in PubMed, Cochrane Library, and Google Scholar to identify original research articles published in English over the past 10 years. Studies at various stages—including in vitro, in vivo, and clinical trials—were included if they evaluated the association between CLEC-2 and acute ischemic stroke. Risk of bias was assessed using the QUIPS tool for clinical studies and SYRCLE’s tool for animal studies. Study selection and data extraction were performed independently by three reviewers. Result: The search identified five relevant articles: two experimental studies and three clinical prognostic studies examining CLEC-2 in the context of ischemic stroke. CLEC-2, a receptor for podoplanin expressed in various tumors and lymphatic endothelial cells, induces a calcium surge independent of secondary platelet activation. In vivo studies have demonstrated increased levels of CLEC-2 and podoplanin, which are highly expressed on neurons and microglia in ischemic brain regions. The three clinical studies showed that plasma CLEC-2 levels have prognostic value in predicting recurrent vascular events and mortality in patients with acute ischemic stroke. Conclusion: Plasma CLEC-2 shows potential as a biomarker for evaluating the progression and prognosis of acute ischemic stroke.

31 October 2024 in Jurnal Respirologi Indonesia
Verified
Journal Article
Open access
PDF file
MRMuhammad Ilham Dhiya Rakasiwi
Muhammad Ilham Dhiya Rakasiwi
DHDiah Handayani
Diah Handayani
Background: The coronavirus disease 2019 (COVID-19) once became a major pandemic in the history of human health. Patients in severe to critical conditions, especially with comorbidities, are more likely to have complications such as ARDS, cytokine storm, higher mortality rates, and require more effective treatments. Emodin is a candidate regimen that has the potential benefit for COVID-19.Method: This literature review was synthesized with literature searches on journal databases such as PubMed, ScienceDirect, EMBASE, and the Google Scholar search engine. As a result, three main articles and 36 supporting articles were used to synthesize this literature review.Results: The pathogenesis of SARS-CoV-2 infection was similar to SARS-CoV infection, as demonstrated by Hoffmann et al, namely through the interaction of viral spike (S) protein with ACE2 receptors in the human body, so the inhibition of this interaction would be one of the therapeutic targets. Ho et al proved that emodin can inhibit the binding of the SARS-CoV S protein to ACE2 in vitro. The direct inhibition of S protein may also support the ACE2 cardioprotective function in patients with cardiovascular comorbidities. Emodin is also superior because it has various other benefits such as anti-inflammatory and immunosuppressive activity. Based on the research of Dong et al, emodin can be given orally but in combination with inhibitors of glucuronidation, metabolism can increase the bioavailability of this drug.Conclusion: Emodin has the potential to be developed for the effective therapy of COVID-19.

25 September 2024 in Malang Respiratory Journal
Verified
Journal Article
Open access
PDF file
MRMuhammad Ilham Dhiya Rakasiwi
Muhammad Ilham Dhiya Rakasiwi
MRMuhammad Ilham Dhiya Rakasiwi
Muhammad Ilham Dhiya Rakasiwi
RFRis Raihan Felim
Ris Raihan Felim
AAAhmad Arfan
Ahmad Arfan
EBErlina Burhan
Erlina Burhan
Background: Acute exacerbations of chronic obstructive pulmonary disease (COPD) are strongly associated with poor health status and morbidity. Erdosteine is a mucolytic agent that also has anti-inflammatory, antioxidant and antibacterial effects. This case report aims to evaluate the role of erdosteine in the prevention and treatment of acute exacerbations of complex COPD case. Case: A 73-year-old male arrived at the emergency department with an increased difficulty in breathing that had deteriorated over the previous 5 days, and had a history of heavy smoking for more than 40 years. Following a thorough examination, he was diagnosed with acute exacerbation of COPD (Anthonisen criteria type 2) in clinical group E, pneumonia, along with stage IIIA right lung tumor (T4N1Mx), and received erdosteine inhalation as part of his treatment. Discussion: A comprehensive search of journal databases (PubMed, EMBASE, CENTRAL, EBSCO Medline, Scopus, and ProQuest) was conducted using specific keywords, critical appraisal based on the Oxford Center for Evidence-Based Medicine. Article selection resulted in 1 systematic review article for the prevention of acute exacerbations and 1 systematic review article for the management of acute exacerbations of COPD. In patients with stable COPD, administration of erdosteine in the standard COPD regimen significantly reduced the risk of exacerbations (RR=0.65; p=0.01), while in patients with acute exacerbations of COPD, erdosteine increased treatment success (OR=3.2; p<0.0001). Conclusion: Erdosteine may serve as a therapeutic choice for COPD patients in preventing or managing acute exacerbations.